EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data

Loading news article.

EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data | WAPE

EXCLUSIVE: TransCode's RNA Therapeutic TTX-MC138 Achieves 64% Stable Disease Rate Lasting Six Months In Phase 1a Trial; Reports Positive Safety And Disease Stabilization Data

Article summary

Related companies

Comments —